RT Journal Article
SR Electronic
T1 Impact of erdosteine on exacerbations in moderate COPD
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 4365
DO 10.1183/13993003.congress-2022.4365
VO 60
IS suppl 66
A1 P M A Calverley
A1 A Papi
A1 C Page
A1 P Rogliani
A1 R Dal Negro
A1 M Cazzola
A1 A Cicero
A1 W Wedzicha
YR 2022
UL http://erj.ersjournals.com/content/60/suppl_66/4365.abstract
AB Impact of erdosteine on exacerbations in moderate COPDIntroduction: Prophylactic treatment with LABA/ICS in moderate COPD affects the number of exacerbations and their treatment (Martinez AJRCCM 2018). Little is known about the effect of antioxidants on exacerbation treatment. We evaluated the effect of erdosteine on exacerbations, antibiotic and oral corticosteroid (OCS) use and health status in moderate COPD.Methods: In this post-hoc analysis of RESTORE study (Dal Negro ERJ 2017), 254 patients with moderate COPD (GOLD 2) received erdosteine 300 mg bid or placebo added to usual therapy for 12 months. We determined antibiotic and OCS use, exacerbation duration and St George’s Respiratory Questionnaire (SGRQ) scores. Subjective COPD severity scores were rated at baseline, 6 and 12 months. A p value <0.05 was considered nominally significant.Results: With erdosteine 43/126 patients exacerbated (7 moderate), compared to 62/128 with placebo (14 moderate). Erdosteine-treated patients with moderate or severe exacerbations took OCS on fewer days compared to placebo (11.4 vs 13.3), required less antibiotics (71.4% vs 85.8%) (p <0.05). Total OCS exposure was significantly less with erdosteine (p<0.05) due to shorter treatment periods (p<0.04). Erdosteine-treated patients who exacerbated showed greater improvements in SGRQ with significantly more reporting a 4 point decrease in total score despite their exacerbation (p<0.001). Similar changes were seen in subjective disease severity scores, regardless of exacerbation severity.Conclusions: In GOLD 2 patients erdosteine decreased the frequency and changed the treatment of exacerbations, lessening their impact. Preventing exacerbations in moderate COPD produces clinically meaningful benefits.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 4365.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).